Clinical study of irbesartan combined with recombinant human brain natriuretic peptide in the treatment of congestive heart failure
10.13699/j.cnki.1001-6821.2015.08.003
- VernacularTitle:厄贝沙坦联合重组人脑利钠肽治疗充血性心力衰竭的临床疗效及安全性评价
- Author:
Qian XIAN
1
;
Rui-Na HUANG
;
Keng WU
Author Information
1. 广东医学院 附属医院
- Keywords:
irbesartan;
recombinant human brain natriuretic peptide;
congestive heart failure;
clinical effect;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(8):592-594
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effects and safety of irbe-sartan combined with recombinant human brain natriuretic peptide on congestive heart failure .Methods A total of 66 patients with congestive heart failure were randomly divided into control group ( n=32 ) and ex-periment group( n=34).Patients in the control group were treated with irbesartan 150 mg? d-1 , po for a month and patients in the experiment were treated with recombinant human brain natriuretic peptide 1.5μg? kg -1 by intravenous drip followed by 7.5 ng? kg -1? min-1 by in-travenous drip on the basis of control group .After one month treatment , the data of total efficacy , serum index and adverse reactions between the two groups were compared . Results The total effective rate was 68.75% and 88.24% in the control and experiment group , which showed a higher rate in the experiment group with statistical difference (P<0.05).The serum level of norepinephrine (NE), endothelin 1 ( ET-1) , and anti-diuretic hormone ( ADH ) were decreased in both groups after treatment , while the experiment group showed a much lower level than those in the control group ( P<0.05 ) .The adverse reactions between the two groups were not statistically different ( P >0.05 ) . Conclusion Irbesartan combined with recombinant human brain natriuretic peptide can increase the total efficacy of patients with congestive heart failure , improve serum indexes and not increase adverse reactions .
